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Abstract 25 
Background: Vaccination with Bacillus Calmette Guerin (BCG) protects infants against 26 
childhood tuberculosis however the immune mechanisms involved are not well understood.  27 
Further elucidation of the infant immune response to BCG will aid with the identification of 28 
immune correlates of protection against tuberculosis and with the design of new improved 29 
vaccines. The purpose of this study was to investigate BCG-induced CD4+ T-cell responses 30 
in blood samples from infants for cytokine secretion profiles thought to be important for 31 
protection against tuberculosis and compare these to PBMC-mediated in vitro mycobacterial 32 
growth inhibition. Methods: Blood from BCG-vaccinated or unvaccinated infants was 33 
stimulated overnight with Mycobacterium tuberculosis (M. tb) purified protein derivative 34 
(PPD) or controls and intracellular cytokine staining and flow cytometry used to measure 35 
CD4+ T-cell responses. PBMC cryopreserved at the time of sample collection were thawed 36 
and incubated with live BCG for four days following which inhibition of BCG growth was 37 
determined.  Results: PPD-specific IFN+TNF+IL-2+ CD4+ T-cells represented the 38 
dominant T-cell response at 4 months and 1 year after infant BCG. These responses were 39 
undetectable in age-matched unvaccinated infants. IL-17+ CD4+ T-cells were significantly 40 
more frequent in vaccinated infants at 4 months but not at 1-year post-BCG. PBMC-mediated 41 
inhibition of mycobacterial growth was significantly enhanced at 4 months post-BCG as 42 
compared to unvaccinated controls. In an analysis of all samples with both datasets available, 43 
mycobacterial growth inhibition correlated significantly with the frequency of polyfunctional 44 
(IFN+TNF+IL-2+) CD4+ T-cells. Conclusions: These data suggest that BCG vaccination 45 
of infants induces specific polyfunctional T-helper-1 and T-helper-17 responses and the 46 
ability, in the PBMC compartment, to inhibit the growth of mycobacteria in vitro. We also 47 
demonstrate that polyfunctional T-helper-1 cells may play a role in growth inhibition as 48 
evidenced by a significant correlation between the two. 49 
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Introduction 53 
A major challenge in the field of tuberculosis (TB) vaccinology is the need for a better 54 
understanding of how Bacillus Calmette-Guerin (BCG), the only licensed vaccine in use 55 
against TB, confers protection in some populations and settings but not others [1-3]. 56 
Knowledge of the mechanisms underlying this difference is vital for the ongoing search for a 57 
better vaccine. One TB vaccine candidate that had proved efficacious in pre-clinical animal 58 
models [4,5] did not give infants significant protection from TB disease [6]. In that clinical 59 
trial, the vaccine, MVA85A, was administered to infants already vaccinated at birth with 60 
BCG with the aim of enhancing any BCG-mediated protection. That this did not occur has 61 
prompted the suggestion that the protection afforded by BCG alone may be difficult to 62 
improve upon and as such, its mechanisms of action deserve greater attention if this is to 63 
happen [7].  64 
Our group has previously provided an immunological description of the different responses 65 
to BCG in United Kingdom (UK) and African populations in which the efficacy of BCG 66 
differs. Malawian adolescents displayed high baseline immune responses to mycobacterial 67 
antigen and BCG did not enhance these. In the UK, adolescents displayed low baseline 68 
responses which were increased significantly following BCG [8]. These observations were 69 
consistent with the hypothesis that exposure to non-tuberculous mycobacteria (NTM) was 70 
masking the response to BCG [9]. In subsequent reports we expanded this description to 71 
infants where, although pre-exposure to NTM was unlikely given the very young age of the 72 
study group, differences in immune response were still observed between the two settings. 73 
UK infants made stronger T helper (Th)-1-type responses including IFN whereas Malawian 74 
infants made stronger Th-2 and regulatory-type responses [10]. Although Th-1 responses, 75 
including cytokines such as IFN and antigen-specific CD4+ T-cells, have been reported not 76 
to correlate with protection against, or risk of, TB disease [11-15], they remain a focus of 77 
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interest for TB vaccinologists due to contrasting evidence where these cells do seem to 78 
correlate with protection against TB [16] as well as the strong evidence in favour of their 79 
importance based on studies of patients with IFN signaling deficiencies [17,18] or with HIV 80 
infection and low CD4 counts [19] who are both susceptible to TB. 81 
A recent development in the field of TB biomarker discovery has been the establishment of 82 
techniques that allow the measurement of mycobacterial growth inhibition in vitro. This 83 
assessment of the capacity of a compartment such as whole blood or peripheral blood 84 
mononuclear cells (PBMC) to inhibit the growth of mycobacteria represents an unbiased 85 
surrogate marker of protection against TB and allows for investigations into the potential 86 
roles of immune mechanisms of interest in mediating this “protective” effect [20-23].   87 
In light of the recent evidence [24] that BCG vaccination in high latitude, low NTM settings 88 
such as the UK might provide important information regarding BCG-induced protective 89 
immunity, we hypothesized that the cytokine immune responses we previously described in 90 
UK infants would originate from antigen-specific helper T-cells. We report here our findings 91 
that BCG vaccination does indeed induce long lasting, polyfunctional Th-1 cellular responses 92 
as well as a more transient Th-17 response in UK infants. We also show that BCG 93 
vaccination induces PBMC-mediated mycobacterial growth inhibition and that 94 
polyfunctional Th-1 responses may play a role in this.  95 
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Materials and Methods 96 
Study participants and sample collection 97 
Healthy infants, born in the UK to mothers with no history of chronic illness including HIV 98 
infection, were recruited after written informed consent was obtained from parents. 99 
Depending upon local health service policy, infants either received a single dose of 100 
intradermal BCG (BCG Vaccine Danish Strain 1331, Staten Serum Institute, Copenhagen, 101 
Denmark) at community clinics (median vaccination age: 5.6 weeks, interquartile range 102 
(IQR): 4.3-8.0 weeks) or did not receive BCG. Heparinised venous blood samples were 103 
obtained from infants at two time points selected to provide data at distinct intervals (4 104 
months and 1 year) following vaccination or at age-matched time points in unvaccinated 105 
infants. Due to variations in availabilities of infant participants and parents, actual median 106 
sampling time points were 15.3 weeks (IQR: 14.4-18.0) and 56.3 weeks (IQR: 54.9-58.0). 107 
Ethical approval for the study was granted by the National Research Ethics Service 108 
Committee London-East (11/LO/0363) and by the Ethics Committee of the London School of 109 
Hygiene and Tropical Medicine. 110 
 111 
Diluted whole blood intracellular cytokine staining (ICS) assay 112 
Venous blood (0.5 mL) was diluted 1:1 with warm Iscove’s Modified Dulbecco’s Medium 113 
(Lonza, Belgium) in 15 mL centrifuge tubes (Corning Inc. NY). Diluted blood was incubated 114 
alone (medium only negative control), with 10 g/ml M. tb PPD batch RT50 for in vitro use; 115 
Statens Serum Institute, Copenhagen, Denmark) or with 5 g/ml staphylococcus enterotoxin 116 
B (SEB; Sigma, UK) as a positive control. Co-stimulatory antibodies (2 g/ml each of anti-117 
CD28 and anti-CD49d (BD Biosciences, Oxford, UK)[25]) were added to all antigen and 118 
control tubes. Assay tubes were incubated with loose lids for 2 hours at 37°C after which 3 119 
g/ml of brefeldin A (Sigma, UK) was added to all tubes which were then incubated for a 120 
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further 18 hours at 37°C. The average time between venipuncture and the initiation of ICS 121 
assay stimulations was 3 hours 16 minutes (SD: 56 minutes). Following incubations diluted 122 
blood was incubated with 10 volumes of 1x PharmLyse solution (BD Biosciences, Oxford, 123 
UK) at room temperature for 10 minutes to lyse red blood cells, centrifuged and washed with 124 
3 mL PBS. Prior to permeabilisation, pelleted cells were surface stained with Vivid live/dead 125 
reagent (Molecular Probes), anti-CD4-APC-H7 (BD Biosciences), anti-CD19-efluor450 and 126 
anti-CD14-efluor450 (eBiosciences) for 30 minutes at 4°C. After washing in PBS + 0.1% 127 
BSA + 0.01% sodium azide, cells were permeabilised with Cytofix/Cytoperm reagent (BD 128 
Biosciences) at 4°C for 20 minutes, washed in Perm Wash buffer (BD Biosciences) and 129 
stained with anti-CD3-Horizon-V500, anti-IL-2-FITC, anti-TNF-PE-Cy7 (BD Biosciences), 130 
anti-IL-17-efluor660, anti-IL-10-PE (eBiosciences) and anti-IFN-PerCP-Cy5.5 (Biolegend) 131 
for 30 minutes at room temperature. Cells were finally resuspended in 250 L 1% 132 
paraformaldehyde (Sigma, UK) and filtered prior to acquisition. Data was acquired using an 133 
LSRII flow cytometer (BD Biosciences) configured with 3 lasers and 10 detectors and 134 
FACSDiva acquisition software (BD Biosciences). Compensation was performed using tubes 135 
of CompBeads (BD Biosciences) individually stained with each fluorophor and 136 
compensation matrices were calculated with FACSDiva.  137 
 138 
PBMC cryopreservation and in vitro mycobacterial growth inhibition assay 139 
For infant blood samples where enough material was available following whole blood ICS 140 
assays, PBMC were prepared by density centrifugation and cryopreserved. Briefly, blood 141 
diluted 1/3 in HBSS (Invitrogen) was layered over Histopaque 1077 (Sigma) and centrifuged 142 
at 800g for 20 minutes. The PBMC layer was transferred to a fresh tube, washed 3 times with 143 
HBSS, frozen in RPMI 1640 (Invitrogen) with 20% foetal bovine serum (FBS; Invitrogen) 144 
and 10% dimethylsulfoxide (Sigma) and stored at -80°C for 24 hours before transfer to liquid 145 
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nitrogen. On thawing, cells were rested for two hours at 37°C in RPMI 1640 with 10% FBS 146 
and 10 units/ml of benzonase (Novagen), then washed and re-suspended in RPMI 1640 with 147 
25 mM HEPES (Sigma) supplemented with 2 mM L-glutamine and 10% filtered, heat-148 
inactivated, pooled human AB serum (Sigma). PBMC (1x106) were added to 2ml screw-cap 149 
microtubes (Sarstedt, Germany) with a pre-determined, optimal quantity of BCG Danish that 150 
equated to 862 cfu and made up to a final volume of 600 μl. Tubes were incubated at 37°C 151 
with 360° rotation for 96 hours. Following incubations, cells and remaining BCG were 152 
pelleted and cells lysed by incubation in sterile water with vortexing. BCG from a single tube 153 
were then transferred into a corresponding MGIT tube and time to positivity determined 154 
using a MGIT 960 (Becton Dickinson). As all assays were carried out simultaneously in a 155 
single batch, direct-to-MGIT controls were not used, as the calculation of relative growth was 156 
not required. 157 
 158 
Data analysis, management and statistical analysis 159 
ICS flow cytometric data was analysed using FlowJo software version 9 (TreeStar Inc.) and 160 
Spice version 5 [26]. Samples were gated sequentially on singlet, live, CD14-CD19-, 161 
lymphoid, CD3+CD4+ cells and negative control stimulation tubes were used to set cytokine 162 
gates (Supplementary Fig. 1). Median cytokine responses in negative control tubes, as a 163 
percentage of the gated CD4+ T-cell population, were as follows: IFN – 0.003%; TNF – 164 
0.002%; IL-2 – 0.002%; IL-17 – 0.002%; IL-10 – 0.003%. Median cytokine responses in 165 
positive control tubes (SEB-stimulated) were as follows: IFN – 0.16%; TNF – 2.05%; IL-2 166 
– 1.77%; IL-17 – 0.11%; IL-10 – 0.06% (Supplementary Fig. 2). Cytokine responses reported 167 
for all stimuli are after subtraction of background values measured in un-stimulated tubes. 168 
The median number of CD4+ T-cell events acquired for all tubes was 298,895 (IQR: 239875-169 
312526).  170 
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All mycobacteria growth inhibition assays were carried out in duplicate. For each tube, time 171 
to positivity in hours was converted to log CFU of bacteria using a previously determined 172 
growth curve for the stock of BCG used. 173 
All statistical comparisons between the magnitudes of ICS and growth inhibition responses 174 
between vaccinated and unvaccinated groups were made using the Mann-Whitney U test. 175 
Associations between growth inhibition and ICS responses were measured using Spearman’s 176 
rank correlation coefficient.  177 
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Results 178 
BCG-vaccination of infants at 6 weeks of age induces antigen-specific, polyfunctional Th-1 179 
cells that persist up to at least 1 year post-vaccination 180 
In order to assess the ability of infant BCG vaccination to activate cytokine-secreting helper 181 
T-cells we used a diluted whole blood ICS assay and PPD stimulation to measure the 182 
frequency of mycobacteria antigen-specific CD4+ T-cell responders at an early and a later 183 
time point following vaccination. CD4+ T-cells expressing IFN, TNF and IL-2 were 184 
detectable at 4 months and 1 year after vaccination but not in age-matched samples from 185 
unvaccinated infants (Fig. 1A-C). The application of Boolean gating to determine the pattern 186 
of cytokine co-expression revealed that at both 4 months and 1 year, IFN+TNF+IL-2+ 187 
polyfunctional T-cells formed the dominant responder population in BCG-vaccinated infants. 188 
The overall responder profile, which also included TNF+IL-2+ double positive and TNF+ 189 
single positive populations, was almost identical at both time points after vaccination (Fig. 190 
1D). These data support the conclusion that BCG vaccination of UK infants activates an 191 
antigen-specific, polyfunctional Th-1 response that is still detectable one year after 192 
vaccination. 193 
 194 
Antigen-specific Th-17 cells are increased in vaccinated infants at 4 months post-vaccination 195 
compared to unvaccinated controls 196 
In addition to IFN, TNF and IL-2, we also examined CD4+ T-cells for antigen-specific, 197 
IL-17 and IL-10 responses. Although we could not detect any IL-10 response with this 198 
protocol at either time point (data not shown), we did observe a significantly greater 199 
frequency of IL-17+ CD4+ T-cells in vaccinated compared to unvaccinated infants at 4 200 
months (median responses of 0.011% IL-17+ and 0.002% IL-17+ CD4 T-cell respectively; 201 
p=0.0045) but not at 1 year (median responses of 0.007% IL-17+ and 0.006% IL-17+ CD4 T-202 
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cell respectively; p=0.894; Fig. 2A-C). In order to determine whether IL-17+ CD4+ T-cells 203 
were secreting other cytokines, we restricted analysis to all possible IL-17+ signatures (Fig. 204 
2D), which revealed that the dominant secretion profile was IL-17+ single positive events. 205 
Although the response profile was similar at both time points, there was a significant 206 
reduction in the frequency of two less prominent populations at 1 year, namely IL-207 
17+TNFα+IL-2+ triple positive and IL-17+IL-2+ double positive cells (p=0.03 and p=0.009 208 
respectively; Fig. 2D). These data support the conclusion that BCG vaccination of UK infants 209 
activates an antigen-specific Th-17 response that, although prominent at 4 months post-BCG, 210 
at 1-year post-BCG has reduced to a magnitude that is indistinguishable from that seen in 211 
unvaccinated infants. 212 
 213 
PBMC compartment of vaccinated infants displays an increased capacity to inhibit the in 214 
vitro growth of BCG mycobacteria at 4 months post-vaccination 215 
In parallel to diluted whole blood ICS assays, where sample volume permitted, PBMC were 216 
also prepared from infant blood samples and cryopreserved. These PBMC were later thawed 217 
and tested for the capacity to inhibit mycobacterial growth in vitro with an assay used as a 218 
surrogate marker for protective immune responses against Mycobacterium tuberculosis in 219 
vivo. Growth of BCG mycobacteria was significantly inhibited by PBMC from BCG-220 
vaccinated infants at 4 months. The median log CFU measured after 4-day culture was 3.2 as 221 
compared to 5.1 in unvaccinated infants (p<0.001; Fig. 3A). The difference in median log 222 
CFU at 12 months post-vaccination between vaccinated and age-matched unvaccinated 223 
infants however was not significant (4.2 and 5.1 respectively; p=0.294; Fig. 3B). As samples 224 
from vaccinated and unvaccinated infants at both time points exhibited a range of log CFU 225 
values that represented the varying degrees of mycobacterial inhibition, we compared these 226 
data with matching frequencies of polyfunctional (IFNγ+TNFα+IL-2+) and Th-17 (IL-17+) 227 
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CD4 T-cells for those samples where both MGIA and ICS data were available. In order to 228 
avoid including dependent variables in the correlation analysis, where data was available for 229 
one infant at both time points, only the 4-month data was included. There was a significant 230 
degree of inverse correlation between polyfunctional CD4+ T-cell frequency and log CFU 231 
(Spearman r value = -0.709; p=0.013; Fig. 3C) but not between Th-17 CD4 T-cell frequency 232 
and log CFU (Spearman r value = -0.399; p=0.198; Fig. 3D) as measured after growth 233 
inhibition assays.  234 
In summary, BCG vaccination of UK infants induces polyfunctional and Th-17 CD4 T-cells 235 
and bestows upon the PBMC compartment the capacity to inhibit mycobacterial growth. 236 
Further to these observations, there is an association between the magnitude of the 237 
polyfunctional T-cell response and the level of mycobacterial inhibition detected in vitro.  238 
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Discussion 239 
We have measured a population of PPD-specific, CD4+ T-cells that demonstrates 240 
polyfunctional (IFN+TNF+IL-2+) capabilities in infants who have received BCG 241 
vaccination at 6 weeks of age. This population was detectable at 4 months and 1 year post-242 
vaccination, comprised the most abundant population as compared to other possible secretion 243 
profiles at both time points and was absent in unvaccinated infants.  This result complements 244 
previous immune analyses we have carried out on similar infant cohorts where secreted 245 
cytokine responses, including IFN, TNF and IL-2, were observed in vaccinated but not 246 
unvaccinated infants following PPD stimulation of diluted whole blood [27,28], and partly 247 
answers the question as to which cells were secreting cytokines in those studies. A number of 248 
papers have consistently described a more heterogeneous T-helper response in terms of the 249 
cytokine secretion profiles detected following BCG in infants [15,29-31]. Although 250 
IFN+TNF+IL-2+ triple positive cells are usually detectable in those studies, it is often 251 
single cytokine producers, most notably IFN+ Th-1 cells, which are most frequent. In 252 
contrast, we did not detect any single IFN producers and in fact, the only population that 253 
displayed any IFN positivity was expressing all three cytokines. The studies referred to 254 
above were carried out in Africa, therefore it is possible that these differences in response 255 
could be due to the fact that our study was carried out in a northern European setting and so 256 
infant participants comprised a different ethnic population who were exposed to a contrasting 257 
set of environmental factors. Another possible explanation for the difference between these 258 
results and those from the African settings could be differences in stimulation protocols, most 259 
notably the use of live BCG mycobacteria as a stimulant in the African studies and our use of 260 
PPD. In addition to this study, others who have used PPD as a stimulant to investigate T-cell 261 
responses following BCG vaccination have also reported prominent polyfunctional responses 262 
in mice and humans [32,33].  263 
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Clearly, the implication of observing a persistent, polyfunctional population of Th-1 cells that 264 
is very specific to having received the BCG vaccine, is that these cells are in some way 265 
involved in the protection that BCG affords these infants against childhood TB [2]. One of 266 
the first flow cytometric descriptions of polyfunctional, cytokine-producing T-cells was in 267 
the context of the protection they conferred to mice following efficacious vaccination against 268 
Leishmania major [34]. The field of TB has produced mixed data regarding the role of 269 
polyfunctional cells in immune protection. Retrospective analysis of samples taken 10 weeks 270 
after BCG vaccination at birth showed no difference in polyfunctional Th-1 cell frequency 271 
when infants who eventually contracted TB disease were compared to those who were 272 
exposed but remained disease-free during a 2 year follow-up period [15]. Another recent 273 
example of polyfunctional Th-1 cells failing to bestow protection against TB was when no 274 
significant protective effect was demonstrated following administration of novel TB vaccine 275 
MVA85A to infants despite this vaccine’s ability to boost antigen-specific, IFN+TNF+IL-276 
2+ CD4 T-cells [6]. Evidently, polyfunctional Th-1 cells do not correlate with risk of TB 277 
disease or protection, respectively, in these studies carried out in African settings, however, 278 
there are other circumstances where polyfunctional T-cell responses are associated with 279 
groups who have proved resistant to the development of TB disease; namely HIV-positive 280 
patients after anti-retroviral therapy with higher CD4 counts or those with lower viral loads 281 
[35,36]. The relatively low TB incidence in the UK combined with the design of our study 282 
means it is not possible to determine whether the Th-1 population we describe here correlates 283 
inversely or directly with risk or protection respectively, although it seems that the field 284 
would benefit greatly from an assessment of the protective capacity of polyfunctional T-cells 285 
in a low NTM, high latitude setting.  286 
In mice, IL-17 responses in the lung were shown to precede an influx of protective Th-1 cells 287 
following vaccination and subsequent infection with M. tb [37] and furthermore, the IL-288 
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23/IL-17 pathway was necessary following BCG vaccination for the effective generation of a 289 
Th-1 response specifically to overcome an otherwise inhibitory IL-10 response [38]. In 290 
addition to polyfunctional Th-1 cells, we also report here a population of PPD-specific, IL-291 
17+CD4+CD3+ cells that are present at a significantly greater frequency in BCG-vaccinated 292 
infants at 4 months post-BCG, as compared to age-matched, unvaccinated infants. Again, this 293 
is consistent with our previous reports of PPD-specific, IL-17 responses detectable in BCG-294 
vaccinated infants [27,28]. The current data provide evidence that the source of at least some 295 
of this IL-17 is antigen-specific Th-17 cells. Unlike Th-1 cellular profiles, Th-17 cells have 296 
been less frequently reported in infant BCG studies, partly due to the more recent emergence 297 
of IL-17 as a cytokine of interest. Where a Th-17 response was sought, in one report it was 298 
not detectable above background levels in control stimulations [39], however in others it was 299 
detectable but did not correlate with risk of TB disease in South African infants [15], nor did 300 
it differ in Ugandan infants who received BCG at birth as compared to those who received it 301 
at 6 weeks of age [31]. We have previously described the complete absence of a PPD-302 
specific, secreted IFN response in unvaccinated UK infants up to 15 months of age [40] and 303 
describe here a concomitant absence of IFN+ Th-1 cells in a similar cohort. This very low 304 
background immune responsiveness to PPD extends to IL-17 and has allowed us to 305 
distinguish an otherwise low frequency Th-17 response at 4 months in vaccinated infants. 306 
However, this differential response at 4 months post-BCG did not extend to samples taken at 307 
1-year post-BCG. It is interesting to note that whilst the frequency of the Th-17 response in 308 
BCG-vaccinated infants is lower at 12 months than at 4 months, the inverse is true of 309 
unvaccinated infants. It has been shown that there is a strong bias towards the development of 310 
Th-17 in neonates [41]. In our study, it may be that this propensity is being illustrated in two 311 
ways. Firstly, in the large increase in PPD-specific Th-17 responses due to BCG vaccination 312 
that gradually wanes by 12 months. Secondly, in the less pronounced increase in Th-17 313 
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responses in BCG unvaccinated infants. That the latter responses were stimulated by PPD 314 
suggests that either these infants have been exposed to environmental mycobacteria or that 315 
there is some cross-reactivity in these Th-17 responses. 316 
We did not detect any IL-10 responses in this study. Although we previously detected PPD-317 
induced IL-10 in BCG vaccinated infants it was in diluted whole blood culture supernatants 318 
after 7 days using multiplex bead array. [27,28]. In this study we used a much shorter 319 
stimulation period (18 hours) and ICS as a detection method and these may be a less sensitive 320 
than is required for IL-10. Another possible explanation is that we restricted our analysis to 321 
CD4+ T-cells in this study and may be missing IL-10 responses from cells such as 322 
monocytes. 323 
In the absence of a TB disease or infection outcome in our cohort we employed instead an in 324 
vitro mycobacteria growth inhibition assay (MGIA) as a surrogate marker of immune 325 
resistance. There is much interest in developing functional assays such as the MGIA as a 326 
surrogate marker of protection in order to facilitate the testing of novel TB vaccines. The aim 327 
is that the MGIA will eventually circumvent the need for long, expensive follow up periods 328 
with TB disease or infection as an endpoint. An additional advantage is that the unbiased 329 
nature of the MGIA means that prior knowledge as to which component of the immune 330 
system is responsible for any protective effect is not necessary. In this study, we found that 331 
the PBMC compartment of vaccinated infants contained the ability to inhibit the growth of 332 
BCG mycobacteria in vitro to a greater extent than that of unvaccinated infants in samples 333 
taken at 4 months. However by 12-month post-BCG there was no difference between the 334 
vaccinated and unvaccinated groups.  A previous study has shown that PBMC from adults 335 
with a history of BCG vaccination inhibit the growth of BCG mycobacteria in vitro to a 336 
greater extent than PBMC from adults without a history of BCG vaccination and that the 337 
capacity to inhibit mycobacterial growth can be induced in the BCG ‘naïve’ adults with 338 
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subsequent, primary vaccination [42]. In another study using a different version of the growth 339 
inhibition assay involving luminescent BCG and whole blood samples, neonatal BCG 340 
vaccination induced a significant degree of mycobacterial growth inhibition that persisted for 341 
up to 6 months when compared to growth inhibition in pre-vaccination samples [43]. Based 342 
on the data available, it is difficult to speculate as to why adults who have had BCG many 343 
years previously may display significantly more growth inhibition than adults with no history 344 
of BCG where as in this study, the difference between vaccinated and unvaccinated infants 345 
lost statistical significance by 12 months post vaccination. The interquartile range of the 12-346 
month post-BCG growth inhibition data was much greater in the vaccinated group. This may 347 
be due to the relatively small sample size and a bigger study with more infants might allow 348 
smaller differences between groups to be detectable that are not here. It should be noted 349 
however that in the Fletcher at al study [42], adults receiving primary BCG vaccination that 350 
displayed significant PBMC-mediated growth inhibition at 4 weeks post-vaccination had 351 
returned to baseline levels by 6 months post-vaccination which is more consistent with the 352 
findings we present here. 353 
The data presented here support the hypothesis that PPD-specific polyfunctional CD4 T-cells 354 
secreting IFNγ, TNFα and IL-2 play a role in mycobacterial growth inhibition in vitro. It is 355 
interesting that three previous studies [21,42,43] did not show any correlation between PPD-356 
specific IFNγ responses measured by ELISA or ELISpot and growth inhibition. To our 357 
knowledge, this is the first time growth inhibition and polyfunctional CD4 T-cells have been 358 
compared in infants and that a correlation is detected might indicate that measuring these 359 
cells is revealing a mechanism that looking at IFNγ alone might be missing.  360 
Our data involves a correlation between ICS responses measured in diluted whole blood and 361 
MGIA responses measured in PBMC, two different cellular compartments. We cannot rule 362 
out possible implications (and limitations) of this, for example, the presence of 363 
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polymorphonuclear cells in ICS assays and their absence in MGIA or the use of non-364 
autologous pooled human serum in MGIA. It would be worth, in future, repeating this 365 
experiment using a whole blood version of the growth inhibition assay to complement the 366 
whole blood ICS in order to investigate the possible impact of this. 367 
In conclusion, the present study expands our previous description of cytokine and chemokine 368 
immune responses in BCG vaccinated UK infants to reveal a prominent, long-lived and 369 
mainly polyfunctional Th-1 response together with the induction of antigen-specific Th-17 370 
cells and that the magnitude of polyfunctional Th-1 cells correlates with in vitro 371 
mycobacterial growth inhibition and may play a role in this effect.372 
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Figure legends 541 
FIGURE 1. Persistent, polyfunctional T helper-1 cells are the dominant, PPD-specific 542 
CD4+ T-cell population in BCG-vaccinated infants.  543 
Venous blood samples obtained 4 months and 1-year post-BCG from vaccinated infants or 544 
from age-matched, unvaccinated infants were stimulated with PPD overnight and CD4+ T-545 
cells assessed for cytokine secretion by intracellular staining. An example of IFN, TNF 546 
and IL-2 co-staining is shown for 4 month (A) and 1 year (B) samples from a BCG 547 
vaccinated (+) and an unvaccinated (−) infant and cumulative composite, single cytokine 548 
expression data (C) for vaccinated and unvaccinated infants at 4 months (dark grey circles) 549 
and 1 year (light grey circles). (D) The polyfunctionality of CD4+ T-cell cytokine responses 550 
in BCG-vaccinated infants at 4 months (dark grey bars) and 1 year (light grey bars). All 551 
composite data plots display boxes showing medians and interquartile ranges. Whiskers, 552 
where included, show the data range. The Mann-Whitney U test was used to determine 553 
significance. Sample numbers are n=24 (BCG-vaccinated infants at 4 months post-BCG); 554 
n=18 (BCG-vaccinated infants at 1 year post-BCG); n=12 (BCG-unvaccinated infants at 4 555 
month time point) and n=15 (BCG-unvaccinated infants at 1 year time point). 556 
 557 
FIGURE 2. PPD-specific T helper-17 response in BCG-vaccinated infants.  558 
An example of IL-17, IFN, TNF and IL-2 co-staining is shown for 4 month (A) and 1 year 559 
(B) samples from a vaccinated (+) and an unvaccinated (−) infant. (C) Cumulative, 560 
composite IL-17 expression data for vaccinated and unvaccinated infants at 4 months (dark 561 
grey circles) and 1 year (light grey circles). (D) The polyfunctionality of all IL-17-expressing 562 
CD4+ T-cell phenotypes in BCG vaccinated infants at 4 months (dark grey bars) and 1 year 563 
(light grey bars). Sample numbers are n=24 (BCG-vaccinated infants at 4 months post-BCG); 564 
n=18 (BCG-vaccinated infants at 1 year post-BCG); n=12 (BCG-unvaccinated infants at 4 565 
 28 
month time point) and n=15 (BCG-unvaccinated infants at 1 year time point). Statistics for 566 
comparisons between vaccinated and unvaccinated infants are Mann-Whitney U tests. * 567 
indicates p<0.05. 568 
 569 
FIGURE 3. Increased capacity to inhibit the in vitro growth of mycobacteria in PBMC 570 
from BCG-vaccinated infants that correlates with polyfunctional T-cell response. 571 
Cryopreserved PBMC prepared from venous blood samples obtained 4 months and 1 year 572 
post-BCG from vaccinated infants or from age-matched, unvaccinated infants were recovered 573 
and incubated with BCG for 4 days after which remaining mycobacteria were quantified by 574 
BACTEC MGIT tubes. Inhibition of BCG growth is indicated by the log CFU of remaining 575 
mycobacteria after incubation with PBMC obtained at the 4 month (A) or 12 month (B) time 576 
point from BCG-vaccinated (+) or BCG-unvaccinated (-) infants. Sample numbers are n=8 577 
(BCG-vaccinated infants at 4 months post-BCG); n=8 (BCG-vaccinated infants at 1 year 578 
post-BCG); n=7 (BCG-unvaccinated infants at 4 month time point) and n=7 (BCG-579 
unvaccinated infants at 1 year time point). For all infant samples where growth inhibition and 580 
ICS data was available (n=12), scatter plots of log CFU versus frequency of polyfunctional 581 
CD4+ T-cells (C) or versus IL-17+CD4+ T-cells (D) were drawn. Solid symbols indicate 4-582 
month samples; open symbols indicate 12-month samples; circles indicate samples from 583 
vaccinated infants; triangles indicate samples from unvaccinated infants. The Mann-Whitney 584 
U test was used to compare growth inhibition between vaccinated and un-vaccinated groups. 585 
Spearman’s rank correlation coefficient was calculated between growth inhibition and ICS 586 
frequencies and significant correlations (p<0.05) are indicated (*). 587 
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